Literature DB >> 21258098

Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996-2007.

Ben A Lopman1, Aron J Hall, Aaron T Curns, Umesh D Parashar.   

Abstract

BACKGROUND: Diarrhea remains an important cause of morbidity, but until the mid 1990s, hospital admissions for diarrhea in the US adult population were declining. We aimed to describe recent trends in gastroenteritis hospitalizations and to determine the contribution of norovirus.
METHODS: We analyzed all gastroenteritis-associated hospital discharges during 1996-2007 from a nationally representative data set of hospital inpatient stays. Annual rates of discharges by age were calculated. Time-series regression models were fitted using cause-specified discharges as explanatory variables; model residuals were analyzed to estimate norovirus- and rotavirus-associated discharges. We then calculated the annual hospital charges for norovirus-associated discharges.
RESULTS: Sixty-nine percent of all gastroenteritis discharges were cause-unspecified and rates increased by ≥ 50% in all adult and elderly age groups (≥ 18 years of age) from 1996 through 2007. We estimate an annual mean of 71,000 norovirus-associated hospitalizations, costing $493 million per year, with surges to nearly 110,000 hospitalizations per year in epidemic seasons. We also estimate 24,000 rotavirus hospitalizations annually among individuals aged ≥ 5 years.
CONCLUSIONS: Gastroenteritis hospitalizations are increasing, and we estimate that norovirus is the cause of 10% of cause-unspecified and 7% of all-cause gastroenteritis discharges. Norovirus should be routinely considered as a cause of gastroenteritis hospitalization.

Entities:  

Mesh:

Year:  2011        PMID: 21258098     DOI: 10.1093/cid/ciq163

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  85 in total

Review 1.  Role of histo-blood group antigens in primate enteric calicivirus infections.

Authors:  Karol Sestak
Journal:  World J Virol       Date:  2014-08-12

Review 2.  Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review.

Authors:  Rishi Desai; Christal D Hembree; Andreas Handel; Jonathan E Matthews; Benjamin W Dickey; Sharla McDonald; Aron J Hall; Umesh D Parashar; Juan S Leon; Benjamin Lopman
Journal:  Clin Infect Dis       Date:  2012-04-04       Impact factor: 9.079

3.  Editorial Commentary: Challenges to Estimating Norovirus Disease Burden.

Authors:  Catherine Yen; Aron J Hall
Journal:  J Pediatric Infect Dis Soc       Date:  2013-01-25       Impact factor: 3.164

4.  Deciphering the Diversities of Astroviruses and Noroviruses in Wastewater Treatment Plant Effluents by a High-Throughput Sequencing Method.

Authors:  B Prevost; F S Lucas; K Ambert-Balay; P Pothier; L Moulin; S Wurtzer
Journal:  Appl Environ Microbiol       Date:  2015-08-07       Impact factor: 4.792

5.  Noroviruses: the perfect human pathogens?

Authors:  Aron J Hall
Journal:  J Infect Dis       Date:  2012-05-08       Impact factor: 5.226

6.  International society for disease surveillance conference 2011: building the future of public health surveillance.

Authors:  Daniel B Neill; Karl A Soetebier
Journal:  Emerg Health Threats J       Date:  2011-12-06

Review 7.  Norovirus Illnesses in Children and Adolescents.

Authors:  Minesh P Shah; Aron J Hall
Journal:  Infect Dis Clin North Am       Date:  2018-03       Impact factor: 5.982

8.  Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013.

Authors:  Everardo Vega; Leslie Barclay; Nicole Gregoricus; S Hannah Shirley; David Lee; Jan Vinjé
Journal:  J Clin Microbiol       Date:  2013-10-30       Impact factor: 5.948

Review 9.  Economics and financing of vaccines for diarrheal diseases.

Authors:  Sarah M Bartsch; Bruce Y Lee
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

10.  Norovirus vaccine development: next steps.

Authors:  Robert L Atmar; Mary K Estes
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.